Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 vs Blinatumomab in R/R CD19+ B-ALL
NCT07570173Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2026
- Primary completion
- Oct 2033
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of CN201 in B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Merck & Co. Primary endpoints: Complete Remission at 126 days, Adverse Events at 126 days and 2 more. Started May 2026; status: recruiting.
02
Drugs
CN201
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07570173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570173.